Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study
Study confirms standard chemotherapy works as well as intensive versions for Asian patients, simplifying treatment choices.
A prospective observational study + PSM analysis found no PFS or OS advantage for dose-adjusted EPOCH-R versus R-CHOP in DLBCL with high Ki67 expression in an East Asian cohort, with insufficient dose escalation suggesting population-specific tolerability differences may limit this regimen's utility in this demographic. The null result has immediate clinical decision-making value for Asian oncology practice.
What the study was
- Study design
- Prospective observational study with propensity score matching
- Population
- DLBCL patients with high Ki67 expression (≥80%)
- Sample size
- 405
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- PLoS One
Why it surfaced
Clinically relevant null result: DA-EPOCH-R does not improve outcomes over R-CHOP in high-Ki67 DLBCL in East Asian patients, likely due to tolerability issues. Adds population-specific evidence to an ongoing clinical debate. PLoS One.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.